The abstract of our presentation at the 25th Annual Meeting of the The American Society of Gene & Cell Therapy (ASGCT) has been released.
Please refer to the link below for an overview.
    https://www.modalistx.com/cms/wp-content/uploads/2022/05/ASGCT-presentations.pdf

In addition, please refer to the “Abstracts” page on the ASGCT Annual Meeting website below.
    https://annualmeeting.asgct.org/abstracts
    ★ Enter “Modalis” in the “Search By Author” field to see a list of abstracts about our presentation.

＜presentations to be announced＞
1. MDC1A
    Novel Single AAV Vector Treatment for Congenital Muscular Dystrophy Type 1A (MDC1A) Using CRISPR-GNDM® Technology
2. Vector
    NGS Based Evaluation of AAV Genome Integrity for Improved Production and Function
3. Tau
    Robust Suppression of Tau by CRISPR-GNDM® System for Treatment of Tauopathies
4. TTN
    Utilizing CRISPR-GNDM® Mediated Gene Activation of the Extra-Large Gene Titin for the Treatment of Dilated Cardiomyopathy and Other Titinopathies
5. Angelman
    Blocking SNHG14/UBE3A-ATS lncRNA Transcription with Dead Cas9 (CRISPR-GNDM®) Can Un-Silence Paternal UBE3A in an Angelman Syndrome Mouse Model
6. Immunology
    Evaluation of Cas9 Mediated Immune Response Effect on Long Term Transgene Expression in WT Mice and NHPs without Immune Suppressant